Soft Anticholinergic Ester Prodrug for Hyperhidrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperhidrosis, such as topical anticholinergics and Botulinum A neurotoxin (BOTOX), face limitations including systemic side effects, invasive procedures, and the need for repeated injections, with existing soft anticholinergic compounds requiring higher concentrations for comparable efficacy.
Innovation Solution
A 5% concentration of a soft-anticholinergic compound, specifically formulated for topical application, is administered before bedtime to reduce sweat production, offering a safer and more effective alternative with reduced systemic side effects and prolonged duration of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical anticholinergic agents are administered to treat hyperhidrosis, then sweat production is reduced, but systemic side effects occur which limit the dosage that can be safely administered
Solution Approach 1:
The patent applies the soft drug approach by chemically modifying the anticholinergic compound to create a prodrug ester that is rapidly hydrolyzed in vivo. This parameter change in molecular structure allows the compound to be inactive during systemic circulation but activated at the target site, reducing systemic side effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent uses esterification as an intermediary approach, converting the active anticholinergic compound into an inactive ester prodrug. This intermediary form is safely transported through the body and only activates at the target sweat glands through enzymatic hydrolysis, acting as a mediator between systemic safety and local efficacy
2Reliability
If glycopyrrolate is administered topically to reduce sweating, then sweat production is reduced, but common undesirable anticholinergic systemic side effects occur due to elimination as unchanged drug or active metabolite
Solution Approach 1:
The patent fundamentally changes the metabolic parameter of glycopyrrolate by converting it from a stable compound eliminated as unchanged drug to a labile ester prodrug that is rapidly hydrolyzed into inactive metabolites, eliminating the harmful systemic effects while preserving local anticholinergic activity
Solution Approach 2:
The patent converts the harmful property of glycopyrrolate stability (which causes systemic accumulation and side effects) into a beneficial property by esterifying it. The resulting prodrug is designed to be unstable in plasma but stable enough for topical application, transforming the original harm into a controlled activation mechanism at the target site
3Object-affected harmful factors
If existing soft anticholinergic compounds are used to treat hyperhidrosis, then some sweat reduction is achieved, but higher concentrations are required for comparable efficacy to glycopyrrolate
Solution Approach 1:
The patent optimizes the esterification parameters by selecting specific fatty acid chains and ester linkages that provide the ideal balance between skin penetration efficiency and hydrolysis rate, achieving maximum sweat reduction at lower concentrations compared to other soft anticholinergic compounds
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound achieves clinically significant sweat reduction of 25% to 99% for up to 24 hours, comparable to glycopyrrolate, with a preferred dosing regimen that includes a second application after the sleep cycle, providing a non-invasive and convenient treatment option for hyperhidrosis.
Implementation Method 1
Muscarinic receptor antagonists are frequently used therapeutic agents that inhibit the effects of acetylcholine by blocking its binding to muscarinic cholinergic receptors at neuroeffector sites on smooth muscle, cardiac muscle, and gland cells
Implementation Method 2
These novel muscarinic antagonists, just as all other soft drugs, are designed to elicit their intended pharmacological effect at the site of application, but to be quickly metabolized into their designed-in, inactive metabolite upon entering the systemic circulation
Data Source
AI summary
A method of treating hyperhidrosis in a mammalian subject, said method comprising topically administering a composition comprising a compound having the formula (I):wherein R is methyl or ethyl, said compound having the R stereoisomeric configuration at the 2 position and the R, S, or RS stereoisomeric configuration at the 1′ and 3′ position, or being a mixture thereof; in an amount of from about 1.0% to about 25% of said compound, an additional active substance that is an antiperspirant active substance and, optionally, a pharmaceutically acceptable vehicle, to skin of an area of a mammalian subject suffering from hyperhidrosis in a one to four times daily dosing regimen.